Immatics N.V

Immatics N.V. is a clinical-stage biotechnology company focused on developing PRAME-directed immunotherapies that harness engineered T-cell receptors (TCRs) for the treatment of cancer. PRAME is an intracellular protein expressed in more than 50 cancer types that can be targeted by TCRs, overcoming limitations of classical antibodies and CAR T-cell therapies. The company's PRAME franchise includes three product candidates across two therapeutic modalities (cell therapies and bispecifics): anzu-cel (IMA203), the lead PRAME cell therapy in Phase 3 for advanced cutaneous melanoma with FDA Orphan Drug and RMAT designations; IMA203CD8 (GEN2), a second-generation PRAME cell therapy targeting expansion into all advanced PRAME cancers starting with gynecologic cancers; and IMA402, an off-the-shelf, half-life extended TCR bispecific targeting earlier-line PRAME cancers. Immatics also develops IMA401, a MAGEA4/8-targeting bispecific being explored in combination with IMA402 for squamous NSCLC. The company generates revenue through strategic collaboration agreements with Bristol-Myers Squibb and Moderna, utilizing its proprietary XPRESIDENT target discovery platform and XCUBE bioinformatics/AI platform. Immatics has not yet commercialized any products and funds operations through equity financings and collaboration payments. The company employs 678 people across operations in Germany and the United States, including a research and commercial GMP manufacturing facility under construction in Houston, Texas. Updated Jun 8, 2026